Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers

Cancer Investigation

Volumn 14, Issue 5, 1996, Pages 466-480

  Mossman, Brooke T ^a   Kamp, David W ^b   Weitzman, Sigmund A ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CIGARETTE SMOKE;

HUMAN; LUNG CANCER; MESOTHELIOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW;

EID: 0029824687     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609018904     Document Type: Review

References (126)

1. Alleman J, Mossman BT: Asbestos revisited. Sci Am (in press).
2. Health Effects Institute - Asbestos Research: Asbestos in Public and Commercial Buildings: A Literature Review and Synthesis of Current Knowledge. Cambridge, MA, Health Effects Institute - Asbestos Research, 1991, pp 1-A-218.
3. Mossman BT, Bignon J, Corn M, et al: Asbestos: Scientific developments and implication for public policy. Science 247:294-301, 1990.
4. Huncharek M: Asbestos and cancer: Epidemiological and public health controversies. Cancer Invest 12:214-222, 1994.
5. Spengler JD, Ozkaynak H, McCarthy JF, et al: Summary of Symposium on Health Aspects of Exposure to Asbestos in Buildings. Cambridge, MA, Energy and Environmental Policy Center, Harvard University, 1989, pp 1-297.
6. Corn M, Crump K, Farrar DB, et al: Airborne concentrations of asbestos in 71 school buildings. Regul Toxicol Pharmacol 13:99-114, 1991.
7. Council on Scientific Affairs, American Medical Association: Asbestos removal, health hazards and the EPA. JAMA 255:696-697, 1991.
8. Reynolds T: Asbestos-linked cancer rates up less than predicted: News and commentary. J Natl Cancer Inst 84:560-562, 1992.
9. Mossman BT, Gee JBL: Asbestos-related diseases. N Engl J Med 320:1721-1730, 1989.
10. Churg A, Wright JL, Vedal S: Fiber burden and patterns of asbestos-related disease in chrysotile miners and millers. Am Rev Respir Dis 148:25-31, 1993.
11. Guthrie GD Jr, Mossman BT, eds: Health Effects of Mineral Dusts, Reviews in Mineralogy. Vol. 28. Washington, DC, Mineralogical Society of America, 1993, pp 1-584.
12. Gibbs AR: Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax 45:649-659, 1990.
13. Doll R: Mineral fibres in the non-occupational environment: Concluding remarks. In: Non-Occupational Exposure to Mineral Fibres, edited by J Bignon, J Peto, R Saracci. Lyon, France, International Agency for Research on Cancer (IARC Scientific Publication no. 90), 1989, pp 511-529.
14. Churg A: Chrysotile, tremolite, and malignant mesothelioma in man. Chest 93:621-628, 1988.
15. McDonald AD, McDonald JC: Epidemiology of malignant mesothelioma. In: Asbestos-Related Malignancy, edited by K Amman, J Aisner. Orlando, FL, Grune & Stratton, 1987, pp 31-35.
16. Morgan A, Holmes A: Solubility of asbestos and man-made mineral fibers in vitro and in vivo: Its significance in lung disease. Environ Res 39:475-484, 1986.
17. Churg A, Wright JL, Gilks B, et al: Rapid short-term clearance of chrysotile compared with amosite asbestos in the guinea pig. Am Rev Respir Dis 139:885-890, 1989.
18. Becklake MR, Case BW: Editorial: Fiber burden and asbestos-related lung disease: Determinants of dose-response relationships. Am J Respir Crit Care Med 150:1488-1492, 1994.
19. Churg A: Asbestos lung burden and disease patterns in man. In: Health Effects of Mineral Dusts, edited by G Guthrie, BT Mossman. Reviews in Mineralogy. Vol. 28. Washington, DC, Mineralogical Society of America, 1993, pp 410-426.
20. Haque A, Kanz MF: Asbestos bodies in children's lungs. Arch Pathol Lab Med 112:514-518, 1988.
21. Selikoff IJ: Historical developments and perspectives in inorganic fiber toxicity in man. Environ Health Perspect 88:269-276, 1990.
22. Ernster VL, Mustacchi P, Osann KE: Epidemiology of lung cancer. In: Textbook of Respiratory Medicine. Vol II, edited by JF Murray, JA Nadel. New York, WB Saunders, 1994, pp 1504-1527.
23. Lemen RA, Dement JM, Wagoner: Epidemiology of asbestos-related diseases. Environ Health Perspect 20:1-21, 1980.
24. Kipen HM, Lilis R, Suzuki Y, et al: Pulmonary fibrosis in asbestos insulation workers with lung cancer: A radiological and histopathological evaluation. Br J Indust Med 44:96-100, 1987.
25. Hammond EC, Selikoff IJ, Seidman H: Asbestos exposure, cigarette smoking and death rales. Ann NY Acad Sci 330:473-492, 1979.
26. Saracci R: Asbestos and lung carcinoma: An analysis of the epidemiologic evidence on the asbestos-smoking interaction. Int J Cancer 20:327-329, 1977.
27. Byers TE, Vena JE, Rzepka TF: Predilection of lung cancers for the upper lobes: An epidemiologic inquiry. J Natl Cancer Inst 72:1271-1275, 1984.
28. Craighead JE, Abraham JL, Churg A, et al: The pathology of asbestos-associated diseases of the lungs and pleural cavities: Diagnostic criteria and proposed grading schema. Arch Pathol Lab Med 106:540-597, 1982.
29. Raffn E, Lynge E, Korsgaard B: Incidence of lung cancer by histological type among asbestos cement workers in Denmark. Br J Indust Med 50:85-89, 1993.
30. Anttila S, Karjalainen A, Taikina-aho O, et al: Lung cancer in the lower lobe is associated with pulmonary asbestos fiber count and fiber size. Environ Health Perspect 101:166-170, 1993.
31. Auerbach O, Garfinkel L, Parks VR, et al: Histologic type of lung cancer and asbestos exposure. Cancer 54:3017-3021, 1984.
32. Johansson L, Albin M, Jacobsson K, McKoczy Z: Histologic type of lung cancer in asbestos cement workers and in material articles. Br J Indust Med 49:626-630, 1992.
33. Enterline PE: Changing attitudes and opinions regarding asbestos and cancer. Am J Indust Med 20:685-700, 1991.
34. Mannino D, Etzel R, Cobb N: Deaths with asbestosis in the United States, 1968 through 1988. Am Rev Respir Dis 145:334(A), 1992.
35. Doll R: Mortality from lung cancer in asbestos workers. Br J Indust Med 12:81-86, 1955.
36. Davis JMG, Cowie HA: The relationship between fibrosis and cancer in experimental animals exposed to asbestos and other fibers. Environ Health Perspect 88:305-309, 1990.
37. Hughes JM, Weill H: Asbestosis as a precursor of asbestos-related lung cancer: Results of a prospective mortality study. Br J Indust Med 48:229-233, 1991.
38. DeVuyst P, Dumortier P, Jacobovitz D, et al: Environmental asbestosis complicated by lung cancer. Chest 105:1593-1595, 1994.
39. Warnock ML, Isenberg W: Asbestos burden and the pathology of lung cancer. Chest 89:20-26, 1986.
40. Edelman DA: Does asbestosis increase the risk of lung cancer? Int Arch Occup Environ Health 62:345-349, 1990.
41. Turner-Warwick M, Lebowitz M, Burrows B, et al: Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35:496-499, 1980.
42. Merchant JA: Human epidemiology: A review of fiber type and characteristics in the development of malignant and nonmalignant disease. Environ Health Perspect 88:287-293, 1990.
43. Miller A, Lilis R, Godbold J, et al: Relationship of pulmonary function to radiographic interstitial fibrosis in 2611 long term asbestos insulators. Am Rev Respir Dis 145:263-269, 1992.
44. Weiss W: Asbestos-related pleural plaques and lung cancer. Chest 103:1854-1859, 1993.
45. Smith DD: Plaques, cancer and confusion. Chest 105:8-9, 1994.
46. Peto J, Doll R, Herman C, et al: Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg 29:305-355, 1985.
47. Selikoff I: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46:2736-2740, 1980.
48. Light RW: Tumors of the pleura. In: Textbook of Respiratory Medicine. Vol II, edited by JF Murray, JA Nadel. New York, WB Saunders, 1994, pp 2222-2234.
49. Enterline PE, Henderson VL: Geographic patterns for pleural mesothelioma deaths in the United States, 1968-81. J Natl Cancer Inst 79:31-37, 1987.
50. McDonald JC, Sebastien P, McDonald AD, Case B: Epidemiological observations on mesothelioma and the implications for nonoccupational exposure. In: Non-Occupational Exposure to Mineral Fibres, edited by J Bignon, J Peto, R Saracchi. Lyon, France, International Agency for Research on Cancer, IARC Sci Publ 90, 1989, pp 420-427.
51. Vogelzang NJ: Malignant mesothelioma: Diagnosis and management. Semin Oncol 19(Suppl 11):64-71, 1992.
52. Rovia GC, Sartori F, Calabro F, et al: The association of pleural mesothelioma and tuberculosis. Am Rev Respir Dis 126:569-571, 1982.
53. Pass HI, Pogrebniak HW: Malignant pleural mesothelioma. Curr Prob Surg 30:921-1020, 1993.
54. Boutin C, Rey F: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72:389-393, 1993.
55. Hillerdal G: Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 77:321-343, 1983.
56. Beauchamp HD, Kundra NK, Aranson R, et al: The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma. Chest 102:1110-1112, 1992.
57. Moch H, Oberholzer M, Dalquen P, et al: Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. Virchows Arch A Path Anat Histopath 423:19-27, 1993.
58. Nurmien M, Dejmek A, Martensson G, et al: Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin Chem 40:777-780, 1994.
59. Martensson G, Thylen A, Lindquist U, et al: The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 73:1406-1410, 1994.
60. Carbone M, Pass HI, Rizzo P, et al: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9:1781-1790, 1994.
61. Walker C, Rutten F, Yuan X, et al: Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54:3101-3106, 1994.
62. Park S, Schalling M, Bernard A, et al: The Wilms tumor suppressor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nature Genet 4:415-420, 1993.
63. Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72:394-404, 1993.
64. Sugarbaker DJ, Strauss GM, Lynch TJ, et al: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11:1172-1178, 1993.
65. Carr DT, Holoye PY, Hong WK: Bronchogenic carcinoma. In: Textbook of Respiratory Medicine. Vol II, edited by JF Murray, JA Nadel. New York, WB Saunders, 1994, pp 1528-1596.
66. Ruckdeschel JC: Therapeutic options for the treatment of small cell and non-small cell lung cancer. Curr Opin Oncol 5:323-334, 1993.
67. Law MR, Gregor A, Hodson ME, et al: Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 39:255-259, 1984.
68. Mew D, Pass HI: Malignant mesothelionias: A clinical challenge. Contemp Oncol 3(12):50-67, 1993.
69. Smythe WR, Hwang HC, Amin KM, et al: Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system. Cancer Res 54:2055-2059, 1994.
70. Kamp DW, Graceffa P, Pryor W, et al: The role of free radicals in asbestos-induced diseases. Free Rad Biol Med 112:673-720, 1992.
71. Janssen YMW, van Houten B, Borm PJA, et al: Cell and tissue responses to oxidative damage. Lab Invest 69:261-274, 1993.
72. Walker C, Everitt J, Barrett JC: Possible cellular and molecular mechanisms of asbestos carcinogenicity. Am J Indust Med 21:253-273, 1993.
73. Sanden A, Jarvholm B, Larsson S: The risk of lung cancer and mesothelioma after cessation of asbestos exposure: A prospective cohort study of shipyard workers. Eur Respir J 5:281-285, 1992.
74. Petruska JM, Leslie KO, Mossman BT: Enhanced lipid peroxidation in bronchoalveolar lavage of rats after inhalation of crocidolite asbestos. Free Rad Biol Med 11:425-431, 1991.
75. Weitzman SA, Weitberg AB: Asbestos-catalyzed lipid peroxidation and its inhibition by desferrioxamine. Biochem J 225:259-262, 1985.
76. Mossman BT, Marsh JP, Shatos MA: Alteration of superoxide dismutase activity in tracheal epithelial cells by asbestos and inhibition of cytotoxicity by antioxidants. Lab Invest 54:204-212, 1986.
77. Shatos MA, Doherty JM, Marsh JP, et al: Prevention of asbestos-induced cell death in rat lung fibroblasts and alveolar macrophages by scavengers of active oxygen species. Environ Res 44:103-116, 1987.
78. Goodlick LA, Pietras LA, Kane A: Evaluation of the causal relationship between crocidolite asbestos-induced lipid peroxidation and toxicity to macrophages. Am Rev Respir Dis 139:1265-1273, 1989.
79. Mossman BT, Marsh JP, Sesko A, et al: Inhibition of lung injury, inflammation, and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis. Am Rev Respir Dis 141:1266-1271, 1990.
80. Jones RN: Asbestos exposures and thoracic neoplasms. Semin Roentgenol 27:94-101, 1992.
81. Weitzman SA, Graceffa P: Asbestos catalyzes hydroxyl and superoxide radical generation from hydrogen peroxide. Arch Biochem Biophys 228:373-376, 1984.
82. Gulumian M, Van Wyk JA: Hydroxyl radical production in the presence of fibers by a Fenton-type reaction. Chem Biol Interact 62:89-97, 1987.
83. Schapira RM, Ghio AJ, Effros RM, et al: Hydroxyl radicals are formed in the rat lung after asbestos instillation in vivo. Am J Respir Cell Mol Biol 10:573-579, 1994.
84. Lund LG, Aust AE: Iron mobilization from crocidolite asbestos greatly enhances crocidolite-dependent formation of DNA single-strand breaks in φX174 RFI DNA. Carcinogenesis 13:637-642, 1992.
85. 2) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 47:1681-1686, 1987.
86. Driscoll KE: In vitro evaluation of mineral cytotoxicity and inflammatory activity. In: Health Effects of Mineral Dusts. Reviews in Mineralogy. Vol. 28, edited by GD Guthrie Jr, BT Mossman. Washington DC, Mineralogical society of America, 1993, pp 489-512.
87. Weitzman SA, Weitberg AB, Clark E, et al: Phagocytes as carcinogens: Malignant transformation produced by human neutrophils. Science 227:1231-1233, 1985.
88. Rom WN, Bitterman PB, Rennard SI, et al: Characterization of the lower respiratory tract inflammation of nonsmoking individuals with interstitial lung disease associated with chronic inflammation of inorganic dusts. Am Rev Respir Dis 136:1429-1434, 1987.
89. Quinlan TR, Marsh JP, Janssen YMW, et al: Dose-responsive increases in pulmonary fibrosis after inhalation of asbestos. Am J Respir Crit Care Med 150:200-206, 1994.
90. Kamp DW, Dunn MM, Sbalchiero JS, et al: Contrasting effects of alveolar macrophages and neutrophils on asbestos-induced pulmonary epithelial cell injury. Am J Physiol 266:L84-L91, 1994.
91. Shelby MD: The genetic toxicity of human carcinogens and its implications. Mutat Res 204:3-15, 1988.
92. Hei TK, Paio CQ, He ZY, et al: Chrysotile fiber is a strong mutagen in mammalian cells. Cancer Res 52:6305-6309, 1992.
93. Yegles M, Saint-Etienne L, Renier A, et al: Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 9:186-191, 1993.
94. Pelin K, Husgafvel-Pursiainen K, Vallas M, et al: Cytotoxicity and anaphase aberrations induced by mineral fibres in cultured human mesothelial cells. Toxic In Vitro 6:445-450, 1992.
95. Leanderson P, Soderkvist P, Tagesson C, et al: Formation of 8-hydroxydeoxyguanosine by asbestos and man made mineral fibres. Br J Indust Med 45:309-311, 1988.
96. Korkina LG, Durnev AD, Suslova TB, et al: Oxygen radical-mediated mutagenic effect of asbestos on human lymphocytes: Suppression by oxygen radical scavengers. Mutat Res 265:245-253, 1992.
97. Kodama Y, Boreiko CJ, Maness SC, et al: Cytotoxic and cytogenetic effects of asbestos on human bronchial epithelial cells in culture. Carcinogenesis 14:691-697, 1993.
98. Chao CC, Aust AE: Effect of long term removal of iron from asbestos by deferoxamine on subsequent mobilization by other chelators and induction of DNA single-strand breaks. Arch Biochem Biophys 308:64-69, 1994.
99. Kamp DW, Israbian VA, Preussen SE, et al: Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells. Am Rev Respir Dis 147:912A, 1993.
100. Gerde P, Scholander P: Adsorption of benzo(a)pyrene onto asbestos and man-made mineral fibers in an aqueous solution and in a biological model system. Br J Indust Med 31:45:682-688, 1988.
101. Eastman A, Mossman BT, Bresnick E: Influence of asbestos on the uptake of benzo[a]pyrene and DNA alkylation in hamster tracheal epithelial cells. Cancer Res 43:1251-1255, 1983.
102. Graceffa P, Weitzman SA: Asbestos catalyzes the formation of the 6-oxobenzo[a]pyrene radical from 6-hydroxybenzo[a]pyrene. Arch Biochem Biophys 253:481-484, 1987.
103. Arif JM, Khan SG, Asian M, et al: Diminution in kerosene-mediated induction of drug metabolizing enzymes by asbestos in rat lungs. Pharmacol Toxicol 71:37-40, 1992.
104. McFadden D, Wright JL, Wiggs B, et al: Smoking inhibits asbestos clearance. Am Rev Respir Dis 133:372-374, 1986.
105. McFadden D, Wright J, Wiggs B, et al: Cigarette smoke increases the penetration of asbestos fibers into airway walls. Am J Pathol 123:95-99, 1986.
106. Heintz NH, Janssen YM, Mossman BT: Persistent induction of c-fos and c-jun protooncogene expression by asbestos. Proc Natl Acad Sci USA 90:3299-3304, 1993.
107. Ames BN, Gold LS: Mitogenesis increases mutagenesis. Science 249:970-971, 1990.
108. Koizumi A, Tsukada M, Hirano S, et al: Energy restriction that inhibits cellular proliferation by torpor can decrease susceptibility to spontaneous and asbestos-induced lung tumors in A/J mice. Lab Invest 68:728-739, 1993.
109. Sugio K, Kishimoto Y, Virmani AK, et al: K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54:5811-5815, 1994.
110. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al: K-ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos. Int J Cancer 53: 250-256, 1993.
111. Sundaresan V, Ganly P, Haleton P, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 7:1989-1997, 1992.
112. Cote RJ, Jhanwar SC, Novick S, et al: Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51:5410-5416, 1991.
113. Metcalf RA, Welsh JA, Bennett WP, et al: p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610-2615, 1991.
114. Van der Meeren A, Seddon MB, Kispert J, et al: Lack of expression of the retinoblastoma gene is not frequently involved in the genesis of human mesothelioma. Eur Respir Rev 3:177-179, 1993.
115. Mayall FG, Goddard H, Gibbs AR: The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. Histopathology 22:383-386, 1993.
116. Cheng JQ, Jhanwar SC, Klein WM, et al: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Can Res 54:5547-5551, 1994.
117. Taguchi T, Jhanwar SC, Siegfried JM, et al: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53:4349-4355, 1993.
118. Wagner JC, Griffiths DM, Hill RJ: The effect of fibre size on the in vivo activity of UICC crocidolite. Br J Cancer 49:455-458, 1984.
119. Stanton MF, Wrench C: Mechanisms of mesothelioma induction with asbestos and fibrous glass. J Natl Cancer Inst 48:797-821, 1972.
120. Davis JMB, Addison J, Bolton RE, et al: The pathogenicity of long versus short fiber samples of amosite asbestos administered to rats by inhalation and intraperitoneal injection. Br J Exp Pathol 67:415-430, 1986.
121. Wylie AG, Bailey KF, Kelse JW, et al: The importance of width in asbestos fiber carcinogenicity and its implications for public policy. Am Indust Hyg Assoc J 54:239-252, 1993.
122. Jansen YMW, March JP, Absher MP, et al: Oxidant stress responses in human pleural mesothelial cells exposed to asbestos. Am J Respir Crit Care Med 149:795-802, 1994.
123. Janssen YMW, Marsh JP, Absher MP, et al: Expression of antioxidant enzymes in rat lungs after inhalation of asbestos or silica. J Biol Chem 267:10625-10630, 1992.
124. Mossman BT, Craighead JE, MacPherson B: Asbestos-induced epithelial changes in organ cultures of hamster trachea: Inhibition by retinyl methyl ether. Science 207:311-313, 1980.
125. van Poppel G, Kok FJ, Hermus RJ: β-Carotene supplementation in smokers reduces the frequency of micronuclei in sputum. Br J Cancer 66:1164-1168, 1992.
126. Omenn GS, Goodman G, Thornquist M, et al: The β-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res 54:2038-2043, 1994.